CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities PLD is ...

Fifty percent of T2DM patients also have NAFLD, confirmed via ultrasound, with elevated liver enzymes and altered lipid profiles. NAFLD and T2DM are key components of metabolic syndrome, sharing risk ...

Drinking diet soda doesn't cause liver damage but can contribute to fatty liver disease due to artificial sweeteners and other risk factors. Learn more.

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

Credit: Getty Images The inaugural ADPKD guideline introduces new ADPKD nomenclature and offers updated recommendations on therapies to slow disease progression. The inaugural ADPKD guideline from ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...